IP Verse

Crystalline Form Of Abacavir That Is Essentially Free Of Solvent - EP2899193

The patent EP2899193 was granted to Esteve Qumica on Mar 14, 2018. The application was originally filed on Jan 21, 2009 under application number EP14198021A. The patent is currently recorded with a legal status of "Revoked".

EP2899193

ESTEVE QUMICA
Application Number
EP14198021A
Filing Date
Jan 21, 2009
Status
Revoked
Feb 7, 2020
Grant Date
Mar 14, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

FRKELLYDec 14, 2018FRKELLYADMISSIBLE
HAMM & WITTKOPPDec 14, 2018HAMM & WITTKOPPADMISSIBLE
LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBDec 14, 2018BESTADMISSIBLE
TER MEER STEINMEISTER & PARTNER PATENTANWALTE MBBDec 14, 2018TER MEER STEINMEISTER & PARTNERADMISSIBLE
D YOUNGDec 12, 2018D YOUNGADMISSIBLE

Patent Citations (32) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0434450
DESCRIPTIONEP0741710
DESCRIPTIONWO2008037760
DESCRIPTIONWO9852949
DESCRIPTIONWO9921861
DESCRIPTIONWO9939691
OPPOSITIONCN1763040
OPPOSITIONEP0434450
OPPOSITIONEP0741710
OPPOSITIONEP1857458
OPPOSITIONEP1905772
OPPOSITIONEP1939196
OPPOSITIONEP2085397
OPPOSITIONEP2242758
OPPOSITIONUS4355032
OPPOSITIONWO2005049588
OPPOSITIONWO2008037760
OPPOSITIONWO2008074874
OPPOSITIONWO2009092716
OPPOSITIONWO9852949
OPPOSITIONWO9921861
OPPOSITIONWO9939691
OTHERCN1763040
OTHEREP2242758
OTHERUS4355032
OTHERUS5034394
OTHERWO2008037760
OTHERWO9852949
OTHERWO9939691
SEARCHCN1763040
SEARCHUS5034394
SEARCHWO2008037760

Non-Patent Literature (NPL) Citations (47) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- SUSAN M. DALUGE ET AL., NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS, (2000), vol. 19, pages 297 - 327-
OPPOSITION- "1.10 Trocknen", Organikum - Organisch-Chemisches Grundpraktikum, VEB, (19880000), page 33, XP055540290-
OPPOSITION- Anonymous, "(941) Characterization of crystalline and partially crystalline solids by X-ray powder diffraction (XRPD)", USP 37 The United States Pharmacopeia The National Formulary, (20140501), vol. 1, pages 503 - 509, XP055540317-
OPPOSITION- "Chapter 11 Purification", Advanced Practical Organic Chemistry Second Edition, (19980000), pages 184 - 187, XP055539235-
OPPOSITION- "Chapter 3 Solids Recrystallization and Melting Points", Gilbert et al., Experimental Organic Chemistry, Brooks/Cole, (20060000), pages 93 - 101, 114-116, XP055539227-
OPPOSITION- CRIMMINS et al., J Org Chem, (19960000), vol. 61, pages 4192 - 4193-
OPPOSITION- DATTA et al., "Crystal Structures of Drugs: Advances in Determination, Prediction and Engineering", Nature Reviews, (20040000), vol. 3, pages 42 - 57, XP 009079167-
OPPOSITION- EMEA, ICH Topic Q3C, Impurities: Residual Solvents, pages 1 - 18-
OPPOSITION- Gattermann, Die Praxis des organischen Chemikers, Walter de Gruyter, (19820000), pages 69 - 77, XP055539310-
OPPOSITION- GATTERMANN et al., "Die Praxis des Organischen Chemikers", Die Praxis des Organischen Chemikers, WALTER DE GRUYTER, pages 69 - 77, XP055539310-
OPPOSITION- GATTERMANN et al., "Kristallisation", Die Praxis des Organischen Chemikers, Walter de Gruyter, (19820000), pages 69 - 77, XP 055539310-
OPPOSITION- GILBERT et al., "Chapter 3 Solids Recrystallization and Melting Points", Experimental Organic Chemistry - A Miniscale & Microscale Approach Fourth Edition, pages 93 - 101 , 114-116, XP 055539227-
OPPOSITION- GILBERT et al., "Chapter 3 Solids Recrystallization and Melting Points", Experimental Organic Chemistry - A Miniscale & Microsclae Approach, pages 93 - 101, 114 - 116, XP055539227-
OPPOSITION- Guidance for Industry. ANDAs: Pharmaceutical Solid Polymorphism, (20070000), pages 1 - 10-
OPPOSITION- GUILLORY, "5 Generation of Polymorphs Hydrates, Solvates, and Amorphous Solid", Polymorphism in Pharmaceutical Solids, Marcel Dekker, page 183,193, XP055539265-
OPPOSITION- GUILLORY, "5 Generation of Polymorphs Hydrates, Solvates, and Amorphous Solids", Polymorphism in Pharmaceutcial Solids, Marcel Dekker, page 183,193, ISBN 978-0-8247-0237-3, XP 055539265-
OPPOSITION- HARWOOD et al., "Organic Reactions/Purification", Experimental Organic Chemistry - Principles and Practice, (19890000), pages 128 - 137, XP055540234-
OPPOSITION- "Impurities: Guidelline for Residual Solvents Q3C(R4)", ICH Harmonised Tripartite Guideline Q3C, Impurities: Guideline for Residual Solvents, (20090201), pages 1 - 21, XP055493014-
OPPOSITION- "Impurities: Guidelline for Residual Solvents Q3C(R4)", International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, (20090201), pages 1 - 21, XP055493014-
OPPOSITION- Keith Guillory, "Generation of Polymorphs Hydrates, Solvates, and Amorphous Solids", Keith Guillory, Harry G Brittan, Polymorphism in Pharmaceutical Solids, Marecel Dekker, (19990000), page 183,193, ISBN 0-8247-0237-9, XP055539265-
OPPOSITION- "Kristallisation", Die Praxis des organischen Chemikers, WALTER DE GRUYTER, (19820000), pages 69 - 77, XP055539310-
OPPOSITION- LEONARD et al., "Chapter 11 Purification", Advanced Practical Organic Chemistry, (19980000), pages 184 - 187, XP 055539235-
OPPOSITION- LEONARD et al., "Chapter 11 Purification", Advanced Practical Organic Chemistry, (19980000), pages 184 - 187, XP055539235-
OPPOSITION- Leonard et al., "Chapter 11 Purification", Advanced Practical Organic Chemistry second edition, (19980000), pages 184 - 187, XP055539235-
OPPOSITION- MUTSCHLER et al., Arzneimittelwirkungen - Lehrbuch der Pharmakologie and Toxikoloqie, (20010000), page 851-
OPPOSITION- Organikum - Organisch-chernisches Grundpraktikum, VEB, (19840000), pages 44 - 46, XP055540128-
OPPOSITION- "Pharmaceutical Solids: A strategic Approach to Regulatory Considerations", Pharmaceutical Research, (19950000), pages 945 - 954, XP 055399407-
OPPOSITION- STAHL et al., Handbook of Pharmaceutical Salts, (20020000), pages 196 - 197-
OPPOSITION- THOMSON, "Chapter 3 Solids Recrystallization and Melting Points", THOMSON, Gibert et al., Experimental Organic Chemistry A Miniscale & Microscale Approach Fourth Edition, (20060000), pages 93 - 101, 114-116, XP055539227-
OPPOSITION- VINCE et al., "Synthesis of Carbovir and Abacavir from a Carbocyclic Precursor", Curr Prot Nucl Acid Chem, (20060000), pages 14.4.1 - 14.4.8, XP 055539239-
OPPOSITION- VOGEL et al., "Experimental Techniques", Vogel's Textbook of Practical Organic Chemistry Fifth Edition, (19890000), pages 149 - 151, 236, XP055540297-
OPPOSITION- Vince et al., "Synthesis of Carbovir and Abacavir from a Carbocyclic Precursor", Current Protocols in Nucleic Acid Chemistry, (20060000), pages 14.4.1 - 14.4.8, XP055539239
OPPOSITION- VINCE et al., "Synthesis of Carbovir and Abacavir from a Carbocyclic Precursor", Current Protocols in Nucleic Acid Chemistry, (20060000), pages 14.4.1 - 14.4.8, XP055539239
OPPOSITION- VINCE et al., "Synthesis of carbovir and abacavir from a carbocyclic precursor", Curr Prot Nucl Acid Chem, (20060000), XP055539239
OPPOSITION- GOTTLIEB et al., "NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities", J Org Chem, (19970000), vol. 62, pages 7512 - 7515, XP055540196
OPPOSITION- BRYN et al., "Pharmaceutical Solids: A strategic Approach to Regulatory Considerations", Pharm Res, (19950000), vol. 1, no. 7, pages 945 - 954, XP055399407
OPPOSITION- BYRN et al., "Pharmaceutical Solids: A strategic Approach to Regulatory Considerations", Pharmaceutical Research, (19950000), vol. 12, no. 7, pages 945 - 954, XP055399407
OPPOSITION- BYRN et al., "Pharmaceutical Solids: A strategic Approach to Regulatory Considerations", Pharm Res, (19950000), vol. 1, no. 7, pages 945 - 954, XP000996386
OPPOSITION- DATTA et al., "Crystal Structures of Drugs: Advances in Determination, Prediction and Engineering", Nature Reviews, (20040000), vol. 3, pages 42 - 57, XP009079167
OTHER- BYM et al., Pharm Res, (19950000), vol. 1, no. 7, pages 945 - 954-
OTHER- "Chapter 11", Leonard J. et al, Advanced Practical Organic Chemistry. 2nd ed., T.J. International, (20010000), pages 184 - 187, XP055378678-
OTHER- "Chapter 3", Gilbert J. C. et al, Experimental Organic Chemistry, Thomson - Brooks/Cole, (20060000), pages 93 - 101,114-116, XP055378688-
OTHER- GATTERMANN et al., Die Praxis des Organischen Chemikers, (19820000), pages 69 - 77-
OTHER- Harry G. Brittain, Polymorphism in Pharmaceutical Solids, Marcel Dekker, (19990000), page 183,193, XP055378682-
OTHER- Theodor Wieland et al, Die Praxis des organischen Chemikers, WdeG, (19820000), pages 69 - 77, XP055378686-
OTHER- Vince Et Al, "Synthesis of Carbovir and Abacavir from a Carbocyclic Precursor", Current Protocols in Nucleic Acid Chemistry, (20060000), pages 14.4.1 - 14.4.8, XP055275681
OTHER- BYRN S; ET AL, "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", Pharmaceutical Research, (19950700), vol. 12, no. 7, pages 945 - 954, XP000996386

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents